Harbour Investments’s Esperion Therapeutics ESPR Stock Holding History

Harbour Investments’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$439	Hold	139	–	–	﹤0.01%	4396
2026 Q1	$381	Buy	139 +100	+256%	+$317	﹤0.01%	4305
2025 Q4	$144	Hold	39	–	–	﹤0.01%	3711
2025 Q3	$103	Hold	39	–	–	﹤0.01%	3639
2025 Q2	$38	Hold	39	–	–	﹤0.01%	3560
2025 Q1	$56	Hold	39	–	–	﹤0.01%	3495
2024 Q4	$86	Hold	39	–	–	﹤0.01%	3413
2024 Q3	$64	Hold	39	–	–	﹤0.01%	3337
2024 Q2	$87	Buy	+39	New	+$92	﹤0.01%	3217
2023 Q4	–	Sell	-7	Closed	-$7	–	3143
2023 Q3	$7	Hold	7	–	–	﹤0.01%	2980
2023 Q2	$10	Hold	7	–	–	﹤0.01%	3012
2023 Q1	$11	Hold	7	–	–	﹤0.01%	2981
2022 Q4	$44	Buy	+7	New	+$50	﹤0.01%	2962
2021 Q4	$0	Sell	76 -100	-57%	-$801	﹤0.01%	2948
2021 Q3	$2K	Hold	176	–	–	﹤0.01%	3295
2021 Q2	$4K	Buy	176 +100	+132%	+$2.41K	﹤0.01%	3133
2021 Q1	$2K	Buy	+76	New	+$2.24K	﹤0.01%	3208

Other funds holding ESPR

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Harbour Investments's ESPR Position: Q2 2026 in Review

Harbour Investments held its Esperion Therapeutics (ESPR) position steady in Q2 2026 at 139 shares worth $439. The position accounts for ﹤0.01% of the portfolio, ranked #4396.

Harbour Investments first reported a position in ESPR in Q1 2021 and has held it in 17 quarters since. The position peaked at $4K in Q2 2021. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

Harbour Investments held 139 shares of Esperion Therapeutics worth $439 as of Q2 2026.
Harbour Investments left its Esperion Therapeutics share count unchanged in Q2 2026.
Esperion Therapeutics made up ﹤0.01% of Harbour Investments's portfolio in Q2 2026, its #4396 holding.
Harbour Investments first reported a position in Esperion Therapeutics in Q1 2021 and has held it in 17 quarters since.
Harbour Investments's Esperion Therapeutics position peaked at $4K in Q2 2021.
191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Harbour Investments's 13F filing for Q2 2026, filed 12 Aug 2026.